Christoph Cannon, MD
Cardiovascular Disease · Boston, MANPI 1548227960
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $303,601 of the $402,177 with a category attached, or 75.5%. 25 manufacturers reported payments, led by Amgen at 24.5% of the total. Reporting peaked in 2019 at $138,728 and has fallen 88.6% since, to $15,813 in 2025. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $1888.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$99K
- Boehringer Ingelheim International GmbH$57K
- Merck$48K
- Sanofi US Services Inc.$36K
- Janssen Research & Development, LLC$32K
- E.r. Squibb & Sons, L.L.C.$29K
- plus $103K from 19 others
Across 101 payments — averaging $3262.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$104K
- Amgen$86K
- Pfizer$70K
- Merck$35K
- Regeneron$12K
- Amryt Pharma Holdings Ltd$10K
- plus $11K from 2 others
What the payments were for
- Consulting fees$303,60175%
- Speaking & faculty fees$80,12420%
- Travel & lodging$16,9794%
- Food & beverage$1,4270%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 59 | $98,614 |
| Boehringer Ingelheim International GmbH | 26 | $57,214 |
| Merck | 23 | $47,707 |
| Sanofi US Services Inc. | 2 | $35,574 |
| Janssen Research & Development, LLC | 14 | $31,538 |
| E.r. Squibb & Sons, L.L.C. | 12 | $28,682 |
| Sanofi-aventis U.S. LLC | 15 | $20,595 |
| Eli Lilly | 10 | $20,250 |
| Alnylam Pharmaceuticals Inc. | 7 | $15,160 |
| Novartis | 5 | $10,585 |
| Janssen Global Services, LLC | 3 | $8,220 |
| Pfizer | 5 | $5,812 |
| Amarin Pharma, Inc. | 19 | $5,591 |
| Biogen | 1 | $4,278 |
| Boehringer Ingelheim | 2 | $2,925 |
| Bayer | 1 | $2,250 |
| CSL Behring | 1 | $2,245 |
| Regeneron Healthcare Solutions, Inc. | 1 | $2,048 |
| Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda. | 1 | $1,740 |
| Medtronic | 1 | $900 |
| Stryker | 1 | $162 |
| Edwards Lifesciences | 1 | $27 |
| Cvrx, Inc. | 1 | $27 |
| Astrazeneca UK Limited | 1 | $21 |
| W. L. Gore & Associates, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$402,177 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 167 | $186,425 |
| EliquisApixaban | 112 | $159,101 |
| Praluent PenAlirocumab | 83 | $83,004 |
| XareltoRivaroxaban | 49 | $68,094 |
| JardianceEmpagliflozin | 28 | $42,687 |
| EntrestoSacubitril/Valsartan | 17 | $23,173 |
| Ezetimibe | 359 | $18,965 |
| VascepaIcosapent Ethyl | 18 | $16,518 |
| NexletolBempedoic Acid | 12 | $9,278 |
| Rosuvastatin Calcium | 283 | $6,864 |
| Metoprolol Succinate | 250 | $4,822 |
| Atorvastatin Calcium | 251 | $4,101 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 44 | $1,257 |
| Lisinopril | 132 | $1,199 |
| Amlodipine Besylate | 137 | $1,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $5,812 | $159,101112 claims |
| Boehringer IngelheimJardiance | $2,925 | $42,68728 claims |
| NovartisEntresto | $10,585 | $23,17317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.